Rhumbline Advisers Sells 213,511 Shares of Pfizer Inc. (NYSE:PFE)

Rhumbline Advisers lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,459,636 shares of the biopharmaceutical company's stock after selling 213,511 shares during the period. Rhumbline Advisers owned approximately 0.17% of Pfizer worth $239,707,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of PFE. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Pfizer during the 4th quarter valued at about $30,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 0.2%

NYSE:PFE traded down $0.05 on Monday, hitting $23.45. The stock had a trading volume of 30,415,590 shares, compared to its average volume of 41,047,098. The business's fifty day moving average is $23.12 and its 200 day moving average is $25.05. The company has a market cap of $133.29 billion, a PE ratio of 16.63, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter last year, the company earned $0.82 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.34%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.